PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 3,375 Shares of Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 3,375 shares of the firm’s stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $63.43, for a total transaction of $214,076.25. Following the transaction, the vice president owned 103,901 shares in the company, valued at $6,590,440.43. This represents a 3.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Mark Elliott Boulding also recently made the following trade(s):

• On Friday, October 3rd, Mark Elliott Boulding sold 22,655 shares of PTC Therapeutics stock. The shares were sold at an average price of $65.82, for a total transaction of $1,491,152.10.
• On Monday, October 6th, Mark Elliott Boulding sold 2,266 shares of PTC Therapeutics stock. The shares were sold at an average price of $65.07, for a total transaction of $147,448.62.
• On Thursday, September 11th, Mark Elliott Boulding sold 22,664 shares of PTC Therapeutics stock. The shares were sold at an average price of $61.00, for a total transaction of $1,382,504.00.
• On Friday, September 12th, Mark Elliott Boulding sold 24,585 shares of PTC Therapeutics stock. The shares were sold at an average price of $61.34, for a total transaction of $1,508,043.90.

PTC Therapeutics Trading Up 2.4%

PTC Therapeutics stock opened at $66.01 on Friday. The company has a market capitalization of $5.24 billion, a P/E ratio of 9.47 and a beta of 0.55. The firm’s fifty day simple moving average is $55.45 and its 200-day simple moving average is $50.50. PTC Therapeutics, Inc. has a 1-year low of $35.51 and a 1-year high of $67.40.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.24. The business had revenue of $178.88 million for the quarter, compared to the consensus estimate of $173.01 million. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. PTC Therapeutics’s revenue for the quarter was down 4.2% on a year-over-year basis. During the same quarter last year, the firm earned ($1.29) EPS. PTC Therapeutics has set its FY 2025 guidance at EPS. On average, equities research analysts predict that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on PTCT shares. Robert W. Baird set a $70.00 target price on shares of PTC Therapeutics in a report on Friday, August 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $118.00 target price on shares of PTC Therapeutics in a report on Wednesday, September 3rd. Barclays lifted their target price on shares of PTC Therapeutics from $42.00 to $46.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 29th. Wells Fargo & Company dropped their target price on shares of PTC Therapeutics from $79.00 to $73.00 and set an “overweight” rating on the stock in a report on Wednesday, August 20th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $63.00 price objective (up previously from $60.00) on shares of PTC Therapeutics in a report on Friday, August 8th. Nine equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, PTC Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $69.00.

Institutional Trading of PTC Therapeutics

Institutional investors have recently made changes to their positions in the business. Quantbot Technologies LP boosted its position in shares of PTC Therapeutics by 545.5% during the 1st quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 551 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in PTC Therapeutics by 84.2% in the first quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 320 shares in the last quarter. GAMMA Investing LLC boosted its position in PTC Therapeutics by 86.3% in the first quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 441 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in PTC Therapeutics by 247.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,143 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 814 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in PTC Therapeutics in the first quarter valued at about $61,000.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.